Study details
Enrolling now
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT IDNCT06503146ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
320
Study length
about 4.7 years
Ages
18–120
Locations
1 site in MD
About this study
Researchers are testing whether a new imaging test, using the substance [18F]FAPI-74, can help find certain types of cancer. The trial will compare this new test to another approved test called [18F]-FDG. Participants with specific cancers like pancreatic or lung cancer may be eligible.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [18F]FAPI-74
- 2.Take [18F]FDG
PhasePhase 2
Drug[18F]FDG
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Safety of [18F]FAPI 74 PET imaging
Body systems
Oncology